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Antithrombotic Choice and Timing in
Patients Presenting with
Symptomatic Hemorrhagic
Conversion
Joshua Margolis, Robin Dharia, MD*, Judy Diep, MD

Introduction
• Hemorrhagic conversion is a dangerous complication of
ischemic stroke1
– Bleeding into infarcted area due to tissue injury
• Anticoagulation therapy for stroke prevention increases the
risk of hemorrhagic conversion2
• Anticoagulation medications may currently be overused
– Early anticoagulation therapy after ischemic stroke does
not appear to significantly decrease the risk of recurrent
embolic events3
• Current guidelines from American Stroke Association
emphasize the urgent need for additional research on the
management of acute ischemic stroke4

Introduction

Objectives
& Hypothesis
• Research Question
– What are the most significant risk factors for
hemorrhagic conversion after acute ischemic stroke
relating to choice and timing of antithrombotic
therapy?

• Hypothesis
– Commonly used anticoagulants such as Warfarin and
Aspirin pose a significant risk for hemorrhagic
conversion, outweighing their protective effects
against further embolic events in the first two weeks
after acute ischemic stroke.

Approach & Results
• Medical chart review of patients with hemorrhagic
conversion at the Jefferson Center City Hospital
– No intervention, just an analysis of previous patient
outcomes

• Risk factors studied include:
–
–
–
–
–
–

Antithrombotic therapy
Medication initiation timing after initial stroke
Mechanism and location of stroke
Atrial fibrillation
Chronic disease (hypertension, renal disease, liver disease)
Substance abuse

• Multivariate analysis to look for associations among
the risk factors

Approach & Results
• There is currently insufficient data for a full analysis (n=58)
– Unexpectedly lower rates of patients with hemorrhagic
conversion
– Difficulties obtaining data due to coding variability
• Initial patients were pulled from a list of intracerebral
hemorrhage (ICH) patients
– Mostly hemorrhagic strokes rather than conversions
– Not all hemorrhagic conversions are in the system as a
separate hemorrhagic event
• Interestingly, 25 of the 58 patients bled on aspirin
monotherapy
• More patient data is needed to draw any statistically
significant conclusions

Conclusions
• Once more data is collected, the hope is to
find new associations and evidence that will
aid in the precise treatment of acute ischemic
stroke
• We will identify specific antithrombotic
therapies and timing of therapies that have
strong associations with hemorrhagic
conversion

Future Directions
• Now pulling from a list of ischemic stroke
patients with atrial fibrillation
– Likely to be on anticoagulants --> increased risk of
hemorrhagic conversion
– Continue to increase sample size

• Develop better evidence-based internal
guidelines for acute ischemic stroke treatment
at the Jefferson Comprehensive Stroke Center
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